Hopstem Biotechnology Secures ￥100 Million in Series A++ Funding

(VCBeat) May. 28, 2021 -- Hopstem Biotechnology, a high-tech innovative enterprise focused on the development of clinical cell products based on pluripotent stem cell-directed differentiation, announced the completion of a Series A++ round of nearly 100 million yuan, led by YuanBio Venture Capital, with participation from the old shareholders Longman Capital, Huancheng Venture Capital with the investment.

This round of financing will mainly be used to support the US and China IND application of the hNPC01 human neural progenitor cell product for the treatment of hemiplegia sequela of ischemic stroke of Holder Biotech, the construction of cell production workshop and QC testing room that meet the requirements of FDA GMP, and the development of other innovative products and pipelines.

Hopstem Biotechnology was founded in January 2017, by neuroscientists and stem-cell biologists from Johns Hopkins University. Hopstem Biotechnology holds world-leading expertise in neural differentiation, cell banking and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). The major aims of our company are to apply these cutting-edge technologies to promote biomedical research, diagnoses and therapies of neurological and other disorders.

Their products/services include different types of high quality human neural cells (HopCell^TM neural cells), 2D and 3D models of human nervous system diseases (HopCell^TM disease model), neural stem cell culture, differentiation and maturation reagents (HopCell^TM reagents), cell line establishing services (HopCell^TM cell line services). We also provide services (Hopstem^TM discovery) on biomarker and drug discovery, including drug screening and neurotoxicity testing, as well as clinical trials of neural progenitor cell transplantation in ischemic stroke and brain injury.

Founded at BioBay of Suzhou Industrial Park and portfolio spreading China and globally, YuanBio Venture Capital focuses on early and growth stage life science and healthcare investment. Its total AUM is close to 5 billion RMB. Portfolio includes over 70 companies across BioPharma, MedTech, IVD and Health Services sectors. YuanBio Venture Capital aims to be one of the most successful healthcare venture capital firms in China.

Founded in 2017, Longman Capital focuses on investments in companies engaged in innovative medicine and life science technology in early and early-growth stages. The core team has a wealth of operation and investment experience in the pharmaceutical field. At present, it has initiated and established the third-phase fund, with a management scale of 2 billion yuan.